1. Home
  2. DUO vs CDIO Comparison

DUO vs CDIO Comparison

Compare DUO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.42

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$1.92

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
CDIO
Founded
2011
2017
Country
China
United States
Employees
N/A
17
Industry
Real Estate
Biotechnology: Commercial Physical & Biological Resarch
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
DUO
CDIO
Price
$1.42
$1.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.8K
113.4K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$171,906.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.18
52 Week High
$5.34
$7.91

Technical Indicators

Market Signals
Indicator
DUO
CDIO
Relative Strength Index (RSI) 66.92 40.36
Support Level $1.25 $1.69
Resistance Level $1.78 $2.03
Average True Range (ATR) 0.09 0.16
MACD 0.03 0.05
Stochastic Oscillator 74.37 31.79

Price Performance

Historical Comparison
DUO
CDIO

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Share on Social Networks: